CAR-T therapy for CEA-positive advanced solid tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Skin clinical trials.
This trial tests a new treatment called CAR-T cells that are designed to find and attack cancer cells carrying a protein called CEA. It is for people with advanced colorectal, esophageal, stomach, or pancreatic cancer who have already tried other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your cancer must be advanced (spread or cannot be removed) and be one of these types: colorectal, esophageal, gastric, or pancreatic.
- You must have already tried at least two standard treatments that didn't work or caused bad side effects.
- Your tumor must test positive for a marker called CEA (a protein on the cancer cells), and your blood CEA level must be above 10 ug/L.
- You need to have at least one tumor that can be measured on a scan.
- You must be in fairly good health overall, with adequate heart, lung, kidney, liver, and blood cell counts, and no serious infections or other active cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (called CAR-T) that targets a protein called CEA on cancer cells. It is for people with advanced colorectal, esophageal, stomach, or pancreatic cancer who have already tried standard treatments without success.
This trial tests a new immune cell therapy (CAR-T) designed to attack cancer cells that make a protein called CEA. It may be an option for people with advanced colorectal, esophageal, gastric, or pancreatic cancer who have already tried at least two standard treatments.
This trial tests a new cell therapy called CAR-T that targets cancer cells with a protein called CEA. It is for people with certain advanced cancers that have not responded to standard treatments.
This trial tests a type of immunotherapy called CAR-T, which is designed to recognize and attack cancer cells that have a protein called CEA on their surface. It's for people with advanced cancers like colorectal, esophageal, gastric, pancreatic, lung, or bile duct cancer who have tried at least two standard treatments.
This trial tests a new CAR-T cell therapy that targets CEA, a protein found on certain cancer cells. It's for people with advanced solid tumors like lung or breast cancer who have not responded to other treatments.
This Phase 1 trial tests a customized immune therapy (CAR-T cells) for advanced cancers that have the proteins mesothelin, GPC3, and/or GUCY2C. It may help your body better recognize and kill cancer cells, but early-phase trials mainly focus on safety and learning how well the treatment works.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.